Dr. Dan Streja MD
Clinical Professor of Medicine, UNIVERSITY OF CALIFORNIA, LOS ANGELES
Member of the Healthcare Council
Council Member Biography
Dan Streja, MD, is Clinical Professor of Medicine at the University of California, Los Angeles. He is also Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic, the Diabetes Clinic, and the divisions of Cardiology and Endocrinology at the VA Medical Center of West Los Angeles. Dr. Streja has expertise in the management of diabetes, hypertension, hyperlipidemia and antithrombotic therapy. He is a consultant in endocrinology for a large managed care medical group. Dr. Streja also serves as Medical Director of Infosphere Clinical Research. Previously, he was Professor of Physiology at the University of Manitoba and specialized in the biochemistry of lipids and carbohydrate metabolism. Dr. Streja is a consultant for Abbott, BMS, Bayer, Eli-Lilly, Merck, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Pfizer, Roche and Sankyo. (This is me - Update Profile)
Employment History
- 1979 - Unspecified
- Consultant Endocrinologist, AFFILIATES IN MEDICAL SPECIALTIES MEDICAL GROUP, INC
- 1979 - Unspecified
- Co-director, UNITED STATES DEPT OF VETERANS AFFAIRS - CC
- 1979 - Unspecified
- Clinical Professor of Medicine, UNIVERSITY OF CALIFORNIA, LOS ANGELES
GLG NewsSM Analyses by Dan Streja
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Actos has little to worry about Avandia lawsuits
May 10, 2011
Glaxo May Settle 1,000 More Lawsuits Over Avandia, Patients’ Lawyer Says | www.bloomberg.com
The FDA has practically eliminated Avandia based on either an analysis considered by everybody faulty or on data that were never released to the public. Actos has a different cardiovascular safety profile and Takeda should not and probably will not settle any lawsuits concerning risk of heart attack.
-
Aspirin cuts heart attack but not strokes, but not in everybody
April 24, 2011
Aspirin cuts heart attacks, but not deaths or strokes: study | www.reuters.com
Aspirin is a great drug to take for prevention of heart attacks but is not for everybody: - In women aspirin prevents strokes but not heart attacks - In patients with diabetes and no heart disease it does not seem to work - In patients with poor circulation to the legs it is not strong enoughThe lack of prevention of death might be due to the fact that the patient studied had less heart attacks but did not oblige the investigators by dying for them. Given the right patient aspirin remains a great drug.
-
Analysis of most prescribed drugs is no surprise
April 24, 2011
What Drug Did Doctors Prescribe Most Last Year? | blogs.wsj.com
In times of cost constrains this is no concern. There are additional factors to explain the numbers, some of them related to FDA wisdom:- Multiple new drug applications in metabolic area have been turned down- Propoxiphene was withdrawn increasing dramatically the use of hydrocodone- Atorvastatin is already generic in other countries Others are related to strategy of the Pharmaceuticals:- Lipitor keeps the market share against simvastatin by issuing $4.00 coupons- Advair and Plavix are heavily advertized directly to the consumer As fewer drugs are approved and many drugs are getting old the overall picture is a logical consequence.
-
Outsourcing of compassionate use of drugs?
January 18, 2008
No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal illness have traveled outside the US to purchase hope when our management was offering none. Although in the majority of cases the hope was unjustified, the current decision will encourage healthcare providers residing outside the US to advertise for their services through the internet. The issue should be addressed by the legislators sooner rather than later. Drugs who improve quality of life, awaiting approval for survival indication or drugs looking promising in early clinical trials could be made available to dying patients with informed consent addressing our limitations.
GLG Study Groups with Dan Streja(?)
| Study Group Name | No. Members |
|---|---|
| General Cardiologists (US) | 1362 |
| Heart Failure Specialists (US) | 1083 |
| Physicians who Treat Hypertension (US) | 949 |
| Non-Electrophysiologist Cardiologists (US) | 849 |
| Physicians who Treat Diabetes (US) | 638 |
GLG Live Meetings with Dan Streja(?)
Dan Streja has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.